Welcome to our dedicated page for Atara Biotherape news (Ticker: ATRA), a resource for investors and traders seeking the latest updates and insights on Atara Biotherape stock.
Atara Biotherapeutics (ATRA) is a clinical-stage biopharmaceutical company developing allogeneic T-cell immunotherapies for cancer and serious diseases. The company's news flow typically centers on clinical trial updates, regulatory developments, financial results, and progress in its collaboration with Memorial Sloan Kettering Cancer Center.
For investors tracking ATRA, news coverage focuses on several key areas. Regulatory announcements related to investigational new drug applications, clinical trial authorizations, and interactions with health authorities provide insight into product development timelines. Clinical data releases from ongoing trials of the company's T-cell therapy candidates offer evidence of safety and efficacy that drives valuation. Financial updates including quarterly results and capital raises reveal the company's cash runway and ability to fund multi-year clinical programs.
As a development-stage biotech company, Atara's newsworthy events also include partnership developments related to its MSK collaboration, pipeline updates on product candidates targeting EBV, CMV, and WT1-associated diseases, and manufacturing milestones for its allogeneic cell therapy platform. The company periodically announces leadership changes, intellectual property developments, and presentations at medical conferences that detail scientific progress.
This news page aggregates ATRA announcements and coverage to help you monitor developments that may affect the company's path toward potential product approvals and commercialization. Bookmark this page to track regulatory progress, clinical trial outcomes, and strategic decisions that shape Atara Biotherapeutics' position in the immunotherapy sector.
Atara Biotherapeutics has granted 37,538 restricted stock units to five newly hired employees as part of its 2018 Inducement Plan, approved by the Compensation Committee of its Board of Directors. The awards, announced on April 1, 2022, vest over four years, incentivizing employee retention. This initiative aligns with Nasdaq Listing Rule 5635(c)(4), highlighting Atara's commitment to employee engagement as it advances its T-cell immunotherapy platform to develop therapies for cancer and autoimmune diseases.
Atara Biotherapeutics (NASDAQ: ATRA) announces the appointment of Charlene Banard as Chief Technical Officer. Banard will oversee process science, quality, and manufacturing. CEO Pascal Touchon highlighted her extensive experience in advanced therapies, including CAR T. Previously, Banard served at Novartis and Shire, where she managed global quality and advanced product pipelines. Atara is known for its innovative T-cell immunotherapies targeting serious diseases, with its lead program in Phase 3 clinical development for EBV-driven conditions.
Atara Biotherapeutics has announced the acquisition of its cell therapy manufacturing facility in Thousand Oaks, California, by FUJIFILM Diosynth Biotechnologies for USD 100 million. This strategic move, coupled with a long-term supply agreement, aims to enhance Atara's capacity for clinical and commercial-stage allogeneic cell therapies, including promising candidates like tabelecleucel and ATA188 for multiple sclerosis. The agreement is expected to reduce Atara's operating expenses and provide financial support into Q4 2023, aiding in the development of innovative therapies.
Eikon Therapeutics has appointed Dr. Roy D. Baynes as Executive Vice President and Chief Medical Officer, effective July 11, 2022. Dr. Baynes, a distinguished oncologist with extensive experience, previously held senior roles at Merck and Amgen, contributing to the development of significant drugs like Keytruda. He will lead the company's clinical research and development, leveraging Eikon's advanced technologies in drug discovery. This appointment aims to strengthen Eikon's ability to deliver innovative therapies for serious illnesses.
Atara Biotherapeutics (NASDAQ: ATRA) will host an EBV and MS Day on March 22, 2022, from 4:00 p.m. EDT. CEO Dr. Pascal Touchon and the management team will discuss the role of Epstein-Barr virus (EBV) in multiple sclerosis (MS), the development of ATA188, and review Phase 1 clinical data. Renowned experts like Mark Freedman and Lawrence Steinman will provide insights. The event includes a conference call for analysts and investors, with a live webcast available on atarabio.com.
Atara Biotherapeutics (NASDAQ: ATRA) reported granting 45,040 restricted stock units and 39,978 stock options to newly hired employees. These awards were approved by Atara’s Compensation Committee and are part of the 2018 Inducement Plan. The restricted stock units will vest over four years, with 25% vesting on the first anniversary. The stock options have a ten-year term and an exercise price of $10.21 per share. This announcement aligns with Nasdaq Listing Rule 5635(c)(4) requirements.
Atara Biotherapeutics (NASDAQ: ATRA) will have its CEO, Pascal Touchon, participate in a cell therapy panel at the Cowen 42nd Annual Virtual Healthcare Conference on March 9, 2022, at 9:10 a.m. EST. The event emphasizes Atara's leadership in T-cell immunotherapy, particularly leveraging its allogeneic Epstein-Barr virus (EBV) platform for cancer and autoimmune disease treatments. A live webcast will be available on their website, with an archived replay accessible for 30 days post-presentation.
Atara Biotherapeutics (Nasdaq: ATRA) announced that a U.S. BLA submission for tab-cel is not expected in Q2 2022 due to further FDA alignment needed. However, the EU approval is on track for Q4 2022. The company reported a Q4 2021 net loss of $93.3 million and a total operating expense increase of 18% compared to the previous year. Significant advances were made in the development of ATA188 for progressive multiple sclerosis, which has received Fast Track designation from the FDA. Atara also entered a $100 million strategic manufacturing partnership with Fujifilm.
Atara Biotherapeutics (NASDAQ: ATRA) reported a serious adverse event (SAE) related to its autologous mesothelin CAR T therapy, ATA2271, during a Phase 1 study at Memorial Sloan Kettering Cancer Center (MSK). Following this event, MSK temporarily paused patient enrollment in the trial. The SAE involved a patient with prior malignancies and is currently under evaluation. Despite this setback, ongoing IND-enabling work for another CAR-T therapy, ATA3271, is unaffected. Atara emphasizes patient safety and intends to update stakeholders soon.
Atara Biotherapeutics, Inc. (NASDAQ: ATRA) will release its fourth quarter and full year 2021 financial results on February 28, 2022. The announcement will be followed by a live conference call at 4:30 p.m. EST to discuss these results and provide a corporate update. Atara aims to deliver T-cell immunotherapy treatments for serious diseases using its unique Epstein-Barr virus T-cell platform, currently advancing several therapies, including tab-cel® for EBV-driven conditions, and ATA188 targeting multiple sclerosis.
FAQ
What is the current stock price of Atara Biotherape (ATRA)?
What is the market cap of Atara Biotherape (ATRA)?
